Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Axel Grothey(University of Wisconsin Carbone Cancer Center), Marc Ychou(Université de Montpellier), Daniel J. Sargent(National Institute of Agricultural Botany), Lisa Cupit(Alleanza Contro il Cancro), Antoine Adenis(Inserm), Salvatore Siena(University of Milan), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Guillem Argilés(Vall d'Hebron Hospital Universitari), Takayuki Yoshino(University of Tsukuba), Dirk Laurent(Menarini Group (Germany)), Laurent Mineur(Institut Sainte Catherine), Olivier Bouché(CHU Dijon Bourgogne), Richard M. Goldberg(Ontario Institute for Cancer Research), Frank Cihon(Alleanza Contro il Cancro), Alberto F. Sobrero(Ospedale Policlinico San Martino), Carlo Barone(Università Cattolica del Sacro Cuore), Yves Humblet(Deventer Ziekenhuis), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi)
Cited by 24
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k